Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors

Carcinogenesis

Volumn 31, Issue 12, 2010, Pages 2049-2057

  Cittelly, Diana M ^a   Das, Partha M ^b   Salvo, Virgilio A ^c   Fonseca, Juan P ^d   Burow, Matthew E ^d   Jones, Frank E ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Tulane University   (United States)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 DELTA 16; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MICRORNA; MICRORNA 15A; MICRORNA 16; PLACEBO; PROTEIN BCL 2; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CELL INVASION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR RESISTANCE; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; MICE; MICE, NUDE; MICRORNAS; RECEPTOR, ERBB-2; TAMOXIFEN;

EID: 78649786164     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq192     Document Type: Article

References (38)

1. Fabbri,M. et al. (2008) MicroRNAs. Cancer J., 14, 1-6.
2. Esquela-Kerscher,A. et al. (2006) Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer, 6, 259-269.
3. Verghese,E.T. et al. (2008) Small is beautiful: microRNAs and breast cancer-where are we now? J. Pathol., 215, 214-221.
4. Tavazoie,S.F. et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147-152.
5. Miller,T.E. et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(Kip1). J. Biol. Chem., 283, 29897-29903.
6. Zhao,J.J. et al. (2008) MicroRNA-221/222 negatively regulates ERalpha and associates with tamoxifen resistance in breast cancer. J. Biol. Chem., 283, 31079-31086.
7. Fisher,B. et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 90, 1371-1388.
8. Early Breast Cancer Trialists' Collaborative Group. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-1467.
9. Normanno,N. et al. (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer, 12, 721-747.
10. Osborne,C.K. et al. (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol., 23, 1616-1622.
11. Osborne,C.K. et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Inst., 95, 353-361.
12. Benz,C.C. et al. (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24,85-95.
13. Kurokawa,H. et al. (2000) Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60, 5887-5894.
14. Liu,B. et al. (2007) Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int. J. Cancer, 120, 1874-1882.
15. Massarweh,S. et al. (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res., 66, 8266-8273.
16. Wang,L.H. et al. (2006) Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell, 10, 487-499.
17. Massarweh,S. et al. (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res., 68, 826-833.
18. Kwong,K.Y. et al. (1998) A novel splice variant of HER2 with increased transformation activity. Mol. Carcinog., 23, 62-68.
19. Siegel,P.M. et al. (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J., 18, 2149-2164.
20. Mitra,D. et al. (2009) An oncogenic isoform of HER2 promotes metastatic breast cancer and trastuzumab resistance. Mol. Cancer Ther., 8, 2152-2162.
21. Naresh,A. et al. (2008) The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res., 68, 6387-6395.
22. Zhu,Y. et al. (2006) Coregulation of estrogen receptor by estrogen-inducible ERBB4/HER4 establishes a growth promoting autocrine signal in breast cancer. Cancer Res., 66, 7991-7998.
23. Jones,F.E. et al. (1999) ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell. Biol., 147, 77-87.
24. Naresh,A. et al. (2006) The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res., 66, 6412-6420.
25. Mandlekar,S. et al. (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis, 6, 469-477.
26. Wang,T.T. et al. (1995) Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55, 2487-2489.
27. Deng,J. et al. (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell, 12, 171-185.
28. Kang,M.H. et al. (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res., 15, 1126-1132.
29. Cimmino,A. et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA, 102, 13944-13949.
30. Thiantanawat,A. et al. (2003) Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res., 63, 8037-8050.
31. Zhang,G.J. et al. (1999) Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin. Cancer Res., 5, 2971-2977.
32. Cannings,E. et al. (2007) Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res. Treat., 102, 173-179.
33. Henriksen,K.L. et al. (2009) An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol., 48, 522-531.
34. Planas-Silva,M.D. et al. (2007) Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp. Mol. Pathol., 82, 85-90.
35. Bonci,D. et al. (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med.
36. Xia,L. et al. (2008) miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer, 123, 372-379.
37. Si,M.L. et al. (2007) miR-21-mediated tumor growth. Oncogene, 26, 2799-2803.
38. Wickramasinghe,N.S. et al. (2009) Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res., 37, 2584-2595.